First Pharmaceutical Drug to Improve Survival Amongst Patients with Advanced Hepatocarcinoma, Barcelona Hospital Clinic Study

ScienceDaily — International research involving the University Hospital of the University of Navarra, together with other hospitals in Spain, has shown that Sorafenib, an orally administered pharmaceutical medicine, results in patients with primary hepatocarcinomas (liver tumours) to live 40% more on average compared to those not taking the drug. The study, led by the Barcelona Hospital Clinic, will be shortly published in the New England Journal of Medicine.

Back to news